Table 2.

Mean pancreatic enzyme levels at baseline and Week 26 in Chinese patients with T2DM receiving dulaglutide 1.5 mg, stratified by potential influencing factors

Subgroup	n	Pancreatic amylase, U/L		Total amylase, U/L		Lipase, U/L
		BL	W26	BL	W26	BL	W26
Age
< 60 years	143	24.06	30.18	54.78	62.46	38.31	51.42
≥ 60 years	60	28.23	34.23	62.18	69.40	43.63	52.77
Sex
Male	120	25.63	31.77	57.35	64.66	40.18	52.42
Female	83	24.81	30.78	56.42	64.19	39.46	51.00
Duration of diabetes
< 10 years	145	23.99	30.82	55.01	63.51	37.71	51.72
≥ 10 years	58	28.55	32.53	61.86	66.56	45.31	52.00
Baseline weight
< 70 kg	89	24.74	31.22	58.42	65.85	39.67	52.20
≥ 70 kg	114	25.73	31.45	55.84	63.33	40.04	51.50
Body mass index
< 25 kg/m2	88	24.93	31.17	57.11	65.60	39.57	49.74
≥ 25 kg/m2	115	25.57	31.48	56.86	63.61	40.12	53.33
Baseline HbA1c
< 8.5%	123	26.21	32.83	58.02	66.63	40.27	54.86
≥ 8.5%	80	23.89	29.04	55.36	61.07	39.29	47.07
Baseline triglycerides
< 2.3 mmol/L	149	26.38	31.40	57.54	64.18	41.01	51.04
≥ 2.3 mmol/L	54	22.31	31.19	55.41	65.25	36.78	53.98
Concomitant OAMs
Metformin only	87	24.70	31.10	54.91	63.05	39.59	51.23
SU only	30	25.10	30.71	56.47	63.92	39.83	49.29
Metformin + SU	86	25.97	31.76	59.23	65.92	40.20	53.07

BL baseline, HbA1c glycated hemoglobin, OAM oral antihyperglycemic medication, SU sulfonylurea, W26 Week 26